Bd announces intent to separate biosciences and diagnostic solutions business to enhance focus, drive growth and unlock value

Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market valuation  "new bd," built on momentum of bd 2025 strategy, will be well-positioned as a scaled, pure-play medtech leader focused on attractive categories shaping the future of health care biosciences and diagnostic solutions to realize its full market potential as differentiated leader in life sciences tools and diagnostics, with robust innovation pipeline and headroom for growth in key sectors franklin lakes, n.j. , feb. 5, 2025 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced its board of directors has unanimously authorized bd management to pursue a plan to separate bd's biosciences and diagnostic solutions business from the rest of bd to enhance strategic focus and growth-oriented investments and capital allocation for both bd and the separated business and enhance value creation for shareholders.
BDX Ratings Summary
BDX Quant Ranking